Fintel reports that on October 21, 2025, Mizuho initiated coverage of Nurix Therapeutics (NasdaqGM:NRIX) with a Outperform ...

Fintel reports that on October 21, 2025, Barclays maintained coverage of RAPT Therapeutics (NasdaqGM:RAPT) with a Overweight ...

Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $5.62, a high estimate of $7.00, and a low estimate of $3.50. This current average has increased by 60.57% ...

Cidara’s lead candidate, CD388, is a long-acting antiviral prophylactic designed for universal prevention of seasonal and ...

Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a ...

Sionna Therapeutics said it started a Phase 2a proof-of-concept trial evaluating the results of SION-719, a nucleotide binding domain (NBD1) stabilizer, when added to Trikafta, which is the current ...

United Therapeutics (NASDAQ: UTHR) has outperformed the market over the past 15 years by 2.22% on an annualized basis producing an average annual return of 14.48%. Currently, United Therapeutics has a ...

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 17, Summit Therapeutics Inc.

Chugai Pharma & Rani Therapeutics ink agreement to develop and commercialize oral formulation leveraging RaniPill technology: Tokyo Wednesday, October 22, 2025, 12:00 Hrs [IST] Ch ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, today announced that Laura J. Esserman, MD ...